Next Phase Newsletter

A fully integrated healthcare solution provider that was founded in 1993 and is headquartered in China is seeking in-licensing, acquisition, and partnership opportunities. For early stage assets, allocation sizes can be flexible, ranging from $2-10M per deal. The firm can either lead or co-invest in a financing round. The firm prefers companies with a China angle and seeks distribution rights in the Chinese market; however this is not a prerequisite criterion. The firm is currently looking for opportunities throughout North America and China.

The firm considers a wide range of technology sectors including therapeutics, medical devices, diagnostics, and healthcare IT. In therapeutics, the firm is interested in small molecules, biologics, cell and gene therapies, and biosimilars for oncology, women’s health, CNS, pain management, and infectious diseases. The firm seeks assets from preclinical stage to proof-of-concept phase 1. In medical devices, the firm prefers 510K and low-risk devices.

The firm is looking for companies with a complete management team formed by devoted and trustworthy members with domain expertise. The firm typically seeks board representation after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An international investment group based in California looks to make equity investments into early stage companies in the life science and technology sectors. The firm makes investments generally ranging from $50,000 to $500,000 into companies and is generally involved in 2-4 deals per year. The firm is willing to consider companies around the globe.

The firm is generally open to all areas within the life sciences though they tend to avoid drug development opportunities as the capital requirements are too large. The firm has current interest in companies in the bioinformatics spaces utilizing genomics and/or proteomics that aid in the drug discovery process, as well as other implementations of bioinformatics. The firm is also open to medical devices across technology types and indication areas. The firm generally makes investment in the seed and series A stages.

The firm is looking for privately held companies with motivated management teams. The firm looks to take board seats into companies on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of a large biotech firm utilizes an evergreen structure and currently holds $750 million in assets under management. The fund invests separately from its parent and is not mandated to invest in areas of strategic relevance with it parent. The firm makes equity investments in early venture rounds. The firm typically invests up to $10 million initially with a total of $15-25 million going to a single company over multiple financing rounds. The firm is willing to both lead and co-invest in companies located around the globe and could make as many as 5-6 investments over the next year.

The firm invests in therapeutics, medical devices, diagnostics, and healthcare IT. The firm invests in early stages of development, from preclinical through to Phase IIa drug trials for therapeutics; and for medical devices and diagnostics, the firm prefers to invest in companies that are anywhere from in-development to on the market.  The firm is interested in all classes and indications of therapeutics, devices, and diagnostics with their main focus being that the technology be truly innovative and novel. They are not interested in cases of reformulations, repurposing or “me too” ideas. The firm makes approximately 75% of its investment in therapeutics and 25% across medical devices, diagnostics and healthcare IT although they are actively looking to increase exposure in these areas. The firm is also open to investing in laboratory equipment and drug development enabling technologies though this area is less of a focus.

The firm prefers to invest in management teams that have demonstrated prior success in the life science industry and are oriented on the goal of bringing a product to market. The firm is currently most interested in privately held companies and looks to take a board seat following investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the southern United States is currently making investments out of its vintage 2013. The fund currently has approximately $200 under management. The firm is looking to make equity investments in companies ranging from $500,000 to $3million. The firm will invest in companies across the United States and plans to make approximately 3-4 investments over the next 6-9 months.

The firm is currently most interested in areas of personalized medicine diagnostics, particularly in the genomic and proteomic subsectors. Other areas of high interest include: digital health, platform technologies, nutrition, clean environment, and much more selectively drug development and medical devices. The firm has experience in immunology and is more familiar with vaccine and antibody based technologies. The firm is open in terms of indication and considers orphan indications as well but requires strong data and a clear pathway to exit. The firm is looking to invest in early to mid-stage companies and generally does not make seed investments.

The firm invests in privately help companies and will both lead or co-invest. The firm looks to take a board seat in some of its portfolio companies though it is not a requirement. The firm looks for smart and passionate management teams with high levels of experience in the field.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global private equity firm with bases in Hong Kong and the United States is primarily focused on healthcare investments with a particular interest in the life science space. The firm looks to make allocations ranging from $250,000 as the first round in a tranched financing structure to $20 million over the lifetime of the investment and depending on the financial needs of the company. The firm is actively seeking new investments and is open to review opportunities from around the globe.

Within the life science space the firm is interested in therapeutics, medical devices, and diagnostics. The firm is currently most interested in companies with some clinical data however they are open to reviewing pre-clinical stage opportunities as well. The firm is open to biosimilar and repurposed assets, and has a preference for platform technologies but is also open to considering single asset opportunities. The firm is open to review all classes of medical devices and diagnostics. The firm is entirely open in terms of indication.

The firm is open to investing in both private and publically help companies and is currently very interested in making cross over investments. The firm is also very interested in companies that have a plan or ability to enter the Chinese market as the firm can add significant value with this strategy. The firm is open to acting as both a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of global pharmaceutical company based in japan is looking to provide equity capital to seed and venture stage companies in the life science space. The firm is looking to provide companies with as much as $5 million over the lifetime of the investment and plans on making 2-3 investments over the next year. The firm will invest in companies located anywhere around the world.

The firm is currently looking for companies developing Therapeutics and Platform Technologies. The firm is looking for companies in this sector working with small molecules, vaccines and biotherapeutics. Indications of interested include nephrology, cardiovascular, immunology, inflammation, stroke, metabolic disease and the firm is especially interested in companies working with therapies for CNS disorders and orphan indications. Ideal companies will have assets either in preclinical stages or in Phase I of clinical trials.

The firm strongly prefers that the company has a strong management team with experience in the industry. The firm is looking to allocate to companies that will eventually be able to partner long term with its parent company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office investment firm based in the Eastern United States specifically focuses on therapeutics for Cystic Fibrosis, including Adult Stem Cell Therapy. The firm manages an evergreen fund and can provide between $200K and $1M in equity per company. The firm has no specific requirement regarding where the company is located and is actively seeking new investment opportunities.

The firm is interested in all therapies for cystic fibrosis, including adult stem cell therapy. The firm looks for early-stage companies with products in pre-clinical or clinical development. Therapies for cystic fibrosis may include antibiotics, anti-inflammatories, airway surface hydrators, CFTR-modulating treatments, and others.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com